Sentiment-Signal
30,4
Bearisch
Composite Score (0–100)
Insider (25%)
61
2 Insider, 25,0M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | Lyell Immunopharma, Inc. |
|---|---|
| Ticker | LYEL |
| CIK | 0001806952 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 483,6 Mio. USD |
| Beta | -0,07 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 36,000 | -274,448,000 | -16.06 | 340,052,000 | 248,202,000 |
| 2025-09-30 | 10-Q | 15,000 | -38,846,000 | -2.13 | 407,965,000 | 329,121,000 |
| 2025-06-30 | 10-Q | 8,000 | -42,684,000 | -2.89 | 385,453,000 | 298,923,000 |
| 2025-03-31 | 10-Q | 7,000 | -52,195,000 | -0.18 | 429,798,000 | 336,521,000 |
| 2024-12-31 | 10-K | 61,000 | -342,994,000 | -26.23 | 490,859,000 | 382,824,000 |
| 2024-09-30 | 10-Q | 34,000 | -44,583,000 | -3.48 | 619,215,000 | 530,697,000 |
| 2024-06-30 | 10-Q | 13,000 | -45,809,000 | -3.59 | 654,142,000 | 566,501,000 |
| 2024-03-31 | 10-Q | 3,000 | -60,667,000 | -0.24 | 694,220,000 | 603,157,000 |
| 2023-12-31 | 10-K | 130,000 | -234,632,000 | -18.70 | 750,029,000 | 654,952,000 |
| 2023-09-30 | 10-Q | 25,000 | -50,853,000 | -0.20 | 794,989,000 | 697,573,000 |
| 2023-06-30 | 10-Q | 27,000 | -63,890,000 | -0.26 | 835,354,000 | 736,855,000 |
| 2023-03-31 | 10-Q | 65,000 | -66,959,000 | -0.27 | 880,450,000 | 783,826,000 |
| 2022-12-31 | 10-K | 84,683,000 | -183,118,000 | -0.74 | 937,561,000 | 833,252,000 |
| 2022-09-30 | 10-Q | 3,000 | -70,254,000 | -0.28 | 977,269,000 | 820,026,000 |
| 2022-06-30 | 10-Q | 35,741,000 | -36,323,000 | -0.15 | 1,021,674,000 | 868,042,000 |
| 2022-03-31 | 10-Q | 553,000 | -68,144,000 | -0.28 | 1,072,103,000 | 881,249,000 |
| 2021-12-31 | 10-K | 10,650,000 | -250,219,000 | -1.84 | 1,127,406,000 | 929,787,000 |
| 2021-09-30 | 10-Q | 2,755,000 | -48,875,000 | -0.20 | 1,198,334,000 | 986,474,000 |
| 2021-06-30 | 10-Q | 2,628,000 | -62,595,000 | -1.47 | 1,229,867,000 | 1,021,955,000 |
| 2021-03-31 | 10-Q | 2,445,000 | -55,043,000 | -3.19 | -334,048,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | ARCH Venture Partners IX, LLC | 10% Owner | Open Market Purchase | 488,090 | 25.61 | 12,499,984.90 | +1031,2% | |
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | 10% Owner | Open Market Purchase | 488,090 | 25.61 | 12,499,984.90 | +1031,2% | |
| 2026-02-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7,455 | 23.39 | -174,372.45 | -14,4% | |
| 2026-02-11 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -1,671 | 23.39 | -39,084.69 | -3,2% | |
| 2026-02-11 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -1,236 | 23.39 | -28,910.04 | -2,4% | |
| 2026-02-10 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -109 | 23.12 | -2,520.08 | -0,2% | |
| 2026-02-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -438 | 23.12 | -10,126.56 | -0,8% | |
| 2026-02-10 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -254 | 23.12 | -5,872.48 | -0,5% | |
| 2026-02-10 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -147 | 23.12 | -3,398.64 | -0,3% | |
| 2025-12-30 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -936 | 32.32 | -30,251.52 | -2,5% | |
| 2025-12-24 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -1,136 | 38.67 | -43,929.12 | -3,6% | |
| 2025-11-10 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -412 | 16.11 | -6,637.32 | -0,5% | |
| 2025-11-10 | Hill Stephen J. | Officer, Chief Operating Officer | Open Market Sale | -95 | 16.12 | -1,531.40 | -0,1% | |
| 2025-11-10 | Lee Gary K. | Officer, Chief Scientific Officer | Open Market Sale | -138 | 16.16 | -2,230.08 | -0,2% | |
| 2025-11-10 | Bulis Veronica Sanchez | Officer, VP, Corporate Controller | Open Market Sale | -239 | 16.10 | -3,847.90 | -0,3% | |
| 2025-08-21 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -7,257 | 10.54 | -76,517.81 | -6,3% | |
| 2025-08-21 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -1,453 | 10.54 | -15,320.43 | -1,3% | |
| 2025-08-12 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -406 | 10.34 | -4,197.23 | -0,3% | |
| 2025-08-12 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -136 | 10.34 | -1,405.97 | -0,1% | |
| 2025-08-11 | Newton Charles W. | Officer, Chief Financial Officer | Open Market Sale | -131 | 10.53 | -1,378.91 | -0,1% | |
| 2025-08-11 | Seely Lynn | Director, Officer, President and CEO | Open Market Sale | -391 | 10.53 | -4,115.67 | -0,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.